Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
Stephen Padilla, 4 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).

Risk factors for pulmonary hypertension in diazoxide-treated hyperinsulinaemic hypoglycaemia

27 Oct 2019

About 7 percent of diazoxide‐treated paediatric patients with hyperinsulinaemic hypoglycaemia develop pulmonary hypertension (PH), with risk factors including congenital heart disease and fluid overload, as shown in a retrospective study.

The study population comprised 177 hyperinsulinaemic hypoglycaemia patients treated with diazoxide in four regional centres in UK.  PH was diagnosed in 13 patients, resulting in an incidence rate of 7 percent or one in every 14 cases.

Patients who did vs did not develop PH were older at the time of hyperinsulinaemic hypoglycaemia diagnosis (median age, 9 vs 1 day; p<0.001) and were more likely to have an underlying congenital heart disease (62 percent vs 23 percent; p=0.008).

In the PH group, hyperinsulinaemic hypoglycaemia was diagnosed at a median of 9 days, with diazoxide initiated 4 days after diagnosis and reached a maximum dose of 7 mg/kg/d. Most patients (eight of 13) developed PH within 2 weeks of treatment.

PH resolved at a median of 41 days following complete diazoxide discontinuation, but not dose reduction. PH persisted beyond 12 months in three patients.

Significant factors associated with the development of PH included the presence of congenital heart disease (p=0.008) and total fluid volume exceeding 130 mL/kg/d in the immediate 24 hours preceding diazoxide (p=0.019).

Based on our findings, researchers recommended the inclusion of echocardiography and fluid restriction to 130 mL/kg/d prior to diazoxide treatment and immediate discontinuation of diazoxide if PH develops.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
Stephen Padilla, 4 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).